However, for “non-inflamed” breast tumors such as those being estrogen receptor positive (ER+) or human epidermal receptor 2 negative (HER2−) breast tumors, improving the efficacy of immunotherapy remains a challenge [71]. This evidence concerns the gene ESR1 and breast neoplasm.